EUCTR2011-004114-42-BE进行中（未招募）1 期
Fenfluramine as anti-epilepticum in Dravet syndrome.
niversity Hospital Antwerp0 个研究点目标入组 50 人开始时间: 2021年4月6日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •age: 1-50y
- •Dravet syndrome
- •therapyresistent epilepsy
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •cardiological abnormalities
- •follow-up insure
- •medication treated hypertension
- •allergic reaction on fenfluramine
研究者
相似试验
招募中
4 期
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of AgeDravet Syndrome (DS)Children Under 2 YearsNCT06598449University of Colorado, Denver12
Approved For Marketing
不适用
Treatment of Dravet Syndrome With Fenfluramine (Expanded Access Protocol)Dravet SyndromeNCT04437004University of California, Los Angeles
尚未招募
3 期
Fenfluramine for Adult Dravet PatientsDravet SyndromeDravet Syndrome, IntractableNCT05560282University Health Network, Toronto15
进行中（未招募）
1 期
Add-on fenfluramine in Lennox Gastaut epilepsyEUCTR2015-004008-46-BEZ Leuven
进行中（未招募）
1 期
The FENDEEP Study: Fenfluramine for the treatment of different types of developmental and epileptic encephalopathies: a pilot trial exploring epileptic and non-epileptic outcomes. - The FENDEEP StudyEUCTR2021-002821-32-ESeurologia Aplicada, SLP20